Predictors of Financial Toxicity in Patients Receiving Concurrent Radiation Therapy and Chemotherapy

Julie M. Jiang, Jeremy Eichler, William Bodner, Jana Fox, Madhur Garg, Rafi Kabarriti, Allen Mo, Shalom Kalnicki, Keyur Mehta, Amanda Rivera, Justin Tang, Johnny Yap, Nitin Ohri, Jonathan Klein

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Purpose: Financial toxicity (FT) is a significant concern for patients with cancer. We reviewed prospectively collected data to explore associations with FT among patients undergoing concurrent, definitive chemoradiation therapy (CRT) within a diverse, urban, academic radiation oncology department. Methods and Materials: Patients received CRT in 1 of 3 prospective trials. FT was evaluated before CRT (baseline) and then weekly using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Core-30 questionnaire. Patients were classified as experiencing FT if they answered ≥2 on a Likert scale question (1-4 points) asking if they experienced FT. Rate of change of FT was calculated using linear regression; worsening FT was defined as increase ≥1 point per month. χ2, t tests, and logistic regression were used to assess predictors of FT. Results: Among 233 patients, patients attended an average of 9 outpatient and 4 radiology appointments over the 47 days between diagnosis and starting CRT. At baseline, 52% of patients reported experiencing FT. Advanced T stage (odds ratio, 2.47; P = .002) was associated with baseline FT in multivariate analysis. The mean rate of FT change was 0.23 Likert scale points per month. In total, 26% of patients demonstrated worsening FT during CRT. FT at baseline was not associated with worsening FT (P = .98). Hospitalization during treatment was associated with worsening FT (odds ratio, 2.30; P = .019) in multivariate analysis. Conclusions: Most patients reported FT before CRT. These results suggest that FT should be assessed (and, potentially, addressed) before starting definitive treatment because it develops early in a patient's cancer journey. Reducing hospitalizations may mitigate worsening FT. Further research is warranted to design interventions to reduce FT and avoid hospitalizations.

Original languageEnglish
Article number101141
JournalAdvances in Radiation Oncology
Volume8
Issue number3
DOIs
StatePublished - May 1 2023

Fingerprint

Dive into the research topics of 'Predictors of Financial Toxicity in Patients Receiving Concurrent Radiation Therapy and Chemotherapy'. Together they form a unique fingerprint.

Cite this